Novo Nordisk: GLP-1's Concerns Are Overblown
I'm an IMC qualified contributor who's followed financial markets for 5 years and has worked professionally in primary investment research for over 2 years. I'm a generalist who enjoys researching businesses from a buttom's up angle with a deep interest in smaller under covered companies where there is greater opportunity for mis-pricing and finding asymmetric opportunities where the downside is limited.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies me ...